Citius Pharmaceuticals, Inc. (CTXR)
NASDAQ: CTXR · IEX Real-Time Price · USD
0.512
-0.031 (-5.74%)
At close: Jul 2, 2024, 4:00 PM
0.519
+0.007 (1.35%)
After-hours: Jul 2, 2024, 7:53 PM EDT
Citius Pharmaceuticals Stock Forecast
CTXR's stock price has decreased by -59.03% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for CTXR stock has a target of 4.00, which predicts an increase of 681.10% from the current stock price of 0.51.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 31, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for CTXR is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +681.10% | May 31, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +681.10% | Feb 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +681.10% | Aug 10, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $6 → $4 | Strong Buy | Maintains | $6 → $4 | +681.10% | Aug 1, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +1,071.65% | May 30, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
85.27M
EPS This Year
-0.23
from -0.22
EPS Next Year
0.06
from -0.23
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | 127.4M | 211.8M | 353.1M | 460.0M |
| Avg | n/a | 85.3M | 204.9M | 343.0M | 446.8M |
| Low | n/a | 45.0M | 196.0M | 329.5M | 429.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 148.4% | 72.3% | 34.1% |
| Avg | - | - | 140.3% | 67.4% | 30.3% |
| Low | - | - | 129.9% | 60.8% | 25.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.24 | 0.06 | 0.58 |
| Avg | -0.23 | 0.06 | 0.56 |
| Low | -0.23 | 0.06 | 0.54 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | 843.6% |
| Avg | - | - | 816.7% |
| Low | - | - | 780.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.